Agenus Inc AGEN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if AGEN is a good fit for your portfolio.
News
-
Agenus Announces Updated Phase 1 Data and Progress on BOT/BAL Development in Metastatic MSS Colorectal Cancer
-
Agenus Announces Reverse Stock Split of Common Stock
-
Agenus Reports Fourth Quarter and Full Year 2023 Results
-
Agenus Announces Preclinical Data on BMS-986442 (AGEN1777) at AACR 2024
-
Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Thinking about buying stock in Volcon, Abeona Therapeutics, Agenus, Viking Therapeutics, or Compugen?
-
Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report
-
Agenus to Participate in Leerink Partners Global Biopharma Conference
Trading Information
- Previous Close Price
- $5.40
- Day Range
- $4.78–6.14
- 52-Week Range
- $4.78–42.60
- Bid/Ask
- $4.98 / $5.15
- Market Cap
- $104.10 Mil
- Volume/Avg
- 1.7 Mil / 630,134
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 0.62
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body’s immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 389
- Website
- https://www.agenusbio.com
Comparables
Valuation
Metric
|
AGEN
|
XNCR
|
STRO
|
---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | — | 1.74 | 1.53 |
Price/Sales | 0.62 | 6.85 | 1.47 |
Price/Cash Flow | — | — | — |
Price/Earnings
AGEN
XNCR
STRO
Financial Strength
Metric
|
AGEN
|
XNCR
|
STRO
|
---|---|---|---|
Quick Ratio | 0.40 | 7.14 | 4.39 |
Current Ratio | 0.44 | 7.36 | 4.50 |
Interest Coverage | −1.63 | — | −3.34 |
Quick Ratio
AGEN
XNCR
STRO
Profitability
Metric
|
AGEN
|
XNCR
|
STRO
|
---|---|---|---|
Return on Assets (Normalized) | −63.60% | −9.75% | −22.26% |
Return on Equity (Normalized) | — | −11.83% | −57.95% |
Return on Invested Capital (Normalized) | — | −12.77% | −42.52% |
Return on Assets
AGEN
XNCR
STRO
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Rhzcgbxkw | Zybg | $553.3 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Vjpvyjyy | Qhjwjc | $101.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Kqwpwbgmn | Mtchhk | $98.1 Bil | |
MRNA
| Moderna Inc | Rvhmlyhr | Flz | $39.7 Bil | |
ARGX
| argenx SE ADR | Nwvvpwsf | Scy | $21.7 Bil | |
BNTX
| BioNTech SE ADR | Fpzndvgzs | Vvrtt | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Hlvwtqtns | Ctbvm | $18.3 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Tfspfjn | Xwykv | $17.1 Bil | |
RPRX
| Royalty Pharma PLC Class A | Zfjtmpypb | Nccfdsm | $12.5 Bil | |
INCY
| Incyte Corp | Rvsddvxg | Pnvxgv | $11.8 Bil |